A New Era of Coronavirus Testing Is About to Begin
In 24 hours, the testing landscape of the United States has transformed.
Yesterday morning, all of the tests for COVID-19—traditional or rapid—that had received emergency authorization from the Food and Drug Administration required an expensive machine and cost around $40 or more. In the afternoon, the health-care company Abbott announced that it had received FDA authorization to distribute a new type of test. This test requires only a coated-paper card and a small swab, and the scale of its production is stunning: Abbott says it will begin manufacturing 50 million of these tests a month in October. The tests will cost just $5 apiece.
That wasn’t the only news. This morning, the Trump administration announced that it would be purchasing 150 million of these tests from the company. For comparison, states have reported fewer than 75 million tests total over the past six months, according to the COVID Tracking Project at The Atlantic.
Many experts have hailed Abbott’s new test as a huge milestone, and a rapid acceleration . Deployed widely and often enough, tests like Abbott’s might allow for kids to return to school, office workers to
You’re reading a preview, subscribe to read more.
Start your free 30 days